Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. - Wikidata - wikimedia - TriplyDB

Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder.

Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder.

http://www.wikidata.org/entity/Q34721772

about

Prevalence, correlates, disability, and comorbidity of DSM-IV borderline personality disorder: results from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders Current and potential pharmacological treatments for obsessive-compulsive disorder Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD)Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression.Obsessive-Compulsive Disorder, 5-HTTLPR polymorphism and treatment response.On the pharmacotherapy of obsessive-compulsive disorder: is a consensus possible?Sertraline in the treatment of anxiety disorders.Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder Obsessions: the impact and treatment of obsessive-compulsive disorder in children and adolescents.Anxiety Disorders with Comorbid Substance Use Disorders: Diagnostic and Treatment Considerations.More than Medication-Achieving Goals through Psychotherapy in Patients with Obsessive Compulsive Disorder.Management of anxiety disorders: the added challenge of comorbidity.Evidence-based pharmacotherapy of obsessive-compulsive disorder.Anxiety disorders and major depression, together or apart.The search for new off-label indications for antidepressant, antianxiety, antipsychotic and anticonvulsant drugs.From the Bench to the Trench: A Comparison of Sertraline Treatment of Major Depression in Clinical and Research Patient Samples Pharmacotherapies in the management of obsessive-compulsive disorder.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision.Pharmacotherapy of anxious disorders.Childhood anxiety disorders and developmental issues in anxiety.Current management of obsessive and phobic states.Dosing of Selective Serotonin Reuptake Inhibitors Pharmacotherapy for Post-traumatic Stress Disorder In Combat Veterans: Focus on Antidepressants and Atypical Antipsychotic Agents A review of the treatment for refractory obsessive-compulsive disorder: from medicine to deep brain stimulation.Minority participation in randomized controlled trials for obsessive-compulsive disorder.Where does obsessive-compulsive disorder belong in DSM-V?Management of obsessive-compulsive disorder with fluvoxamine extended release Five-year course of obsessive-compulsive disorder: predictors of remission and relapse.Treatment strategies for obsessive-compulsive disorder.A 2012 evidence-based algorithm for the pharmacotherapy for obsessive-compulsive disorder.Pharmacotherapy of obsessive-compulsive disorder: evidence-based treatment and beyond.An updated review of antidepressants with marked serotonergic effects in obsessive-compulsive disorder.Effect of sertraline on proliferation and neurogenic differentiation of human adipose-derived stem cells Psychiatric diagnosis and clinical trial completion rates: analysis of the FDA SBA reports.Contemporary approaches to pharmacotherapy in Tourette's syndrome and obsessive-compulsive disorder.CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6.A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism.Antipanic efficacy of paroxetine and polymorphism within the promoter of the serotonin transporter gene.Latinos with obsessive-compulsive disorder: Mental healthcare utilization and inclusion in clinical trials.

P2860

Q22241102-F2EC5ECF-2747-4139-8FFF-F3657567F47D Q22305681-D380F2FE-23D9-450A-97B1-804ADBDE75FA Q22306025-87DA5D12-4ECB-41B7-BB08-5B39AB133880 Q24242402-1F5B77F4-E3B6-440C-989E-313D08891533 Q32097605-A2984B53-E683-4A8B-830C-289BB93AADBA Q33183862-985730A2-CE7C-4B7F-B0E7-F659B4FA72D7 Q33898364-13EEEBA6-5AEB-4401-BCB4-80A2884F424F Q33914087-CD47D0E0-A76C-4150-9D19-824924222A47 Q33926476-DA584BB1-741C-45AE-98FF-62ED0C882C91 Q33963431-E5B11B45-39D1-4972-9D23-F314C20F7F3D Q34066108-08F4AD7F-8594-4E80-825B-74EEA2C00EAA Q34068960-8F33ABB4-43B7-44B5-921D-E72911104FAF Q34218830-32CCE8BD-FA86-418E-9CDF-34C2EA4DA64E Q34245428-8A1857E9-FDBC-4AB9-8BE1-09DBD1774654 Q34415535-ADFAB823-2E93-49E4-A4C5-05508F14829D Q34525841-9C137198-3756-4B47-A154-B444E1ABCC04 Q34546238-4D3571C8-4A84-4DE1-AD50-01A287D6324A Q34547177-6268CD21-6936-4836-B50A-6F0B02F06244 Q34865036-093F69DD-8DF8-4DCB-913A-814D330C01ED Q35011794-DCFD56F1-8C55-4832-AFCB-2AB5BB410AA3 Q35176158-E08BCBCA-AD58-4F36-860A-BE3F8B679B0A Q35327098-688D53E3-0C93-41F1-9A54-84D4D5BF8ABF Q35666956-6CF61188-D85D-4ABC-99C1-B18EE790816B Q35752941-9369F6C6-9682-4CF0-AEF7-0852BA254BFD Q35936259-D871A818-202A-42A4-83AC-CD0BCC6C8AE2 Q36200991-4C3F4449-3E95-41FE-8447-8630F29B57DD Q37138385-3A9EC9AA-831A-419C-9E76-A3F895AD8259 Q37235709-A9488E69-3AAC-4833-B0EE-D5D5FE7F2248 Q37506023-2A753E4A-0B73-4998-BBB0-805BD81F8CA5 Q37681560-75421DE8-3279-4939-98BD-F2B2F478D929 Q38004948-C2FCD991-706B-4006-A504-E0AE649F91AB Q38057736-18ED73AD-21E8-4998-B972-197410F4C17D Q38207094-8D4C8505-91DC-429F-BF45-D101AC622EFC Q39143491-57E73247-D9E3-4F66-B9FB-214B0939610B Q40240452-EAFC9758-C6EA-4B6D-BB97-ABDBEBFF116E Q41025805-98C683D8-8301-4666-BDE3-DBF5A14A651B Q44098828-A08B8EC4-664E-4CA3-902F-68329FE1F311 Q45189223-34C3F612-E9C3-4461-9FC9-00B408AE3C8E Q46611107-0115E8A3-8743-4D69-A057-36BD965F7CA3 Q47127372-82FB9BD1-D95C-4AF9-A10C-4A520976E7CD

P2860

Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder.

http://www.wikidata.org/entity/Q34721772

description

1995 nî lūn-bûn

@nan

1995 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

1995 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

1995年の論文

@ja

1995年論文

@yue

1995年論文

@zh-hant

1995年論文

@zh-hk

1995年論文

@zh-mo

1995年論文

@zh-tw

1995年论文

@wuu

name

Double-blind parallel comparis ...... obsessive-compulsive disorder.

@ast

Double-blind parallel comparis ...... obsessive-compulsive disorder.

@en

Double-blind parallel comparis ...... obsessive-compulsive disorder.

@nl

type

label

Double-blind parallel comparis ...... obsessive-compulsive disorder.

@ast

Double-blind parallel comparis ...... obsessive-compulsive disorder.

@en

Double-blind parallel comparis ...... obsessive-compulsive disorder.

@nl

prefLabel

Double-blind parallel comparis ...... obsessive-compulsive disorder.

@ast

Double-blind parallel comparis ...... obsessive-compulsive disorder.

@en

Double-blind parallel comparis ...... obsessive-compulsive disorder.

@nl

P1433

Q34721772-152300DC-4CFD-466D-BF62-C61573A26919

P1476

Q34721772-3DE83D21-42CC-401A-A9FB-3037B3F721E5

P2093

Q34721772-391299D1-AC9D-46D3-8F90-1174F1B3AD6E

Q34721772-4AD7F65F-53AC-4F1B-B0D4-06F54CC0961E

Q34721772-4F6F5903-A847-468F-A4C2-6BB3E2F3098D

Q34721772-599923FA-6754-46C2-9354-DC6401F56917

Q34721772-66E3E334-C72A-401A-85F6-9B2416E8A4BA

Q34721772-90C0AB01-A6B3-4EB1-B7AE-5A9EB1D4DA3D

Q34721772-B0BEE47A-23D9-4540-9794-29CC4A4838F1

Q34721772-C08A58E2-9858-40F7-8AA1-BF8678880707

Q34721772-F418665E-2983-480D-83BC-34E04A3A913D

Q34721772-FE417A19-8EF7-4B95-AD42-DF74A9A68ED7

P304

Q34721772-CCB0E758-12FB-411D-8576-BEA358FF5EA3

P31

Q34721772-F7395F73-2A82-4519-9542-272C87DA9273

P356

Q34721772-8E7A6A79-FB9C-4D70-B071-53FD29775F50

P407

Q34721772-421D9D23-D1BC-4E39-A845-0659FA0DD306

P433

Q34721772-7EAA5525-A72A-4AE2-8647-A488AB3AE655

P478

Q34721772-D21CC485-25CE-4417-B184-9254C8954C7C

P577

Q34721772-20A732E4-013E-4A9C-A603-D7B58380567D

P5875

Q34721772-D0D78CAD-C083-4D86-85E2-5EC0772E3E38

P698

Q34721772-CC6205AD-E01B-4576-B3CB-B36A62916726

P921

Q34721772-EF7298F7-D080-42E9-955E-7BACF51A8D47

P356

ARCHPSYC.1995.03950160039008

P1433

JAMA Psychiatry

P1476

Double-blind parallel comparis ...... obsessive-compulsive disorder.

@en

P2093

Chouinard G

http://www.w3.org/2001/XMLSchema#string

DuBoff E

http://www.w3.org/2001/XMLSchema#string

Greist J

http://www.w3.org/2001/XMLSchema#string

Halaris A

http://www.w3.org/2001/XMLSchema#string

Kim SW

http://www.w3.org/2001/XMLSchema#string

Koran L

http://www.w3.org/2001/XMLSchema#string

Liebowitz M

http://www.w3.org/2001/XMLSchema#string

Lydiard RB

http://www.w3.org/2001/XMLSchema#string

Rasmussen S

http://www.w3.org/2001/XMLSchema#string

White K

http://www.w3.org/2001/XMLSchema#string

P304

289-295

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/ARCHPSYC.1995.03950160039008

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P577

1995-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

15497610

http://www.w3.org/2001/XMLSchema#string

P698

7702445

http://www.w3.org/2001/XMLSchema#string

P921